Eli Lilly and Company (TSX:LLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.15T +8.5% |
| Revenue (ttm) | 89.37B +44.7% |
| Net Income | 28.30B +94.9% |
| EPS | 31.47 +96.0% |
| Shares Out | n/a |
| PE Ratio | 40.59 |
| Forward PE | 26.68 |
| Dividend | 0.22 (0.65%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 104,801 |
| Average Volume | 35,506 |
| Open | 33.35 |
| Previous Close | 33.20 |
| Day's Range | 33.35 - 35.25 |
| 52-Week Range | 22.85 - 41.00 |
| Beta | n/a |
| RSI | 49.92 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Novo VP Weighs In on Approval of Lilly's Obesity Pill
Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More ...
Pricing and availability of Novo, Lilly's weight-loss drugs
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker's efforts to expan...
VIEW Lilly gets FDA nod for oral obesity pill, analysts see strong uptake potential
The U.S. Food and Drug Administration has approved Eli Lilly's weight-loss pill, bringing another oral alternatives to a market dominated by injectables and intensifying competition with Novo Nordisk...
Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says
Eli Lilly opposes the White House's push to codify 'Most Favored Nations' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...
FDA Approves Eli Lilly's Weight Loss Pill—Second Weight GLP-1 Drug In Pill Form
The Food and Drug Administration has approved Foundayo, Eli Lilly's new GLP-1 pill to treat weight loss—the second oral weight loss drug to hit the market after Novo Nordisk's Wegovy was greenlit last...
America has a new weight-loss drug, and it's a pill
The Food and Drug Administration on Wednesday approved Foundayo, an oral GLP-1 medication that is expected to produce tens of billions of dollars at its peak. Lilly's stock LLY+4.12% jumped 5% after t...
Eli Lilly CEO: Our pill supply can 'reach the planet'
Eli Lilly Chair & CEO Dave Ricks tells CNBC's Angelica Peebles that with the approval of the company's GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the glo...
Eli Lilly Stock Jumps. A Weight-Loss Pill Is Officially on the Market.
Eli Lilly's Foundayo will be available to patients through the drugmaker's online pharmacy.
Lilly's weight-loss pill wins US approval
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight-loss pill, making it the second to market after Novo Nordisk's oral Wegovy, as the companies fight to capture more...
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
Cramer's Mad Dash: Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect ® with...
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenienc...
Stock Of The Day: Where Will Eli Lilly Turn?
Some people believe the market is random. They think it isn't possible to time the market.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Lilly and Novo Show How AI Is Rewiring Big Pharma
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug ...
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
Why Eli Lilly Is Buying Centessa for $7.8 Billion
Bloomberg Intelligence's Sam Fazeli discusses Eli Lilly's $7.8 billion acquisition of Centessa, marking the company's entry into the sleep disorder drug market. He speaks on "Bloomberg Open Interest.
Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, "predictable" monthly prices. Eligible patients can c...
Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion
Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial $6.3 billion in a deal that expands the drugmaker's neuroscience portfolio and capabilities into sleep medici...
Eli Lilly to buy Centessa Pharma in $6.3 billion deal
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal worth about $6.3 billion to advance treatments for sleep-wake disorders.
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lil...